KS Hegde Medical Academy, Endocrinology.
Father Muller Medical College, department of medicine.
Afr Health Sci. 2023 Mar;23(1):270-275. doi: 10.4314/ahs.v23i1.29.
Genitourinary infections are common in Diabetes patients compared to the general population more so in patients with Sodium glucose co transporter 2 inhibitors (SGLT2i) treatment , So, we did a study to find the prevalence of genitourinary infection in T2DM patients treated with SGLT2i.
One hundred and twenty patients receiving SGLT2i, who had signs and symptoms indicative of genitourinary infections were enrolled into the study.
The mean age of presentation was 54.4 ± 7.7 years and percentage of males were 62 (51.66%). In this cohort, 72(60%) were treated with empagliflozin, 34(28.33%) with dapagliflozin and 14(11.66%) with canagliflozin. Twenty patients had genital mycotic infection and 4 had urinary tract infection. Female patients had higher incidence of infections than male patients with no statistically significant difference (P = ns). We did not find any significant correlation between age of the patient, gender, duration of disease and treatment, HbA1c, different types and dose of SGLT2i used with the incidence of genital mycotic infections (P = ns).
We need to counsel the patients before starting SGLT2i regarding possible chance of getting genitourinary infection, proper genital hygiene, drinking plenty of water and consulting the doctor if any symptoms at the earliest.
与普通人群相比，糖尿病患者更易发生泌尿系统感染，尤其是在使用钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT2i）治疗的患者中。因此，我们进行了一项研究，旨在探讨 SGLT2i 治疗的 2 型糖尿病（T2DM）患者中泌尿系统感染的患病率。
我们共纳入了 120 例有泌尿系统感染症状和体征的 SGLT2i 治疗患者。
患者的平均年龄为 54.4 ± 7.7 岁，男性占 62.0%（51.66%）。在该队列中，72 例（60.0%）患者接受恩格列净治疗，34 例（28.33%）患者接受达格列净治疗，14 例（11.66%）患者接受卡格列净治疗。20 例患者患有生殖器真菌性感染，4 例患者患有尿路感染。女性患者的感染发生率高于男性患者，但差异无统计学意义（P = ns）。我们未发现患者年龄、性别、病程和治疗、糖化血红蛋白（HbA1c）、SGLT2i 的不同类型和剂量与生殖器真菌性感染发生率之间存在显著相关性（P = ns）。
我们需要在开始 SGLT2i 治疗前向患者提供有关可能发生泌尿系统感染的风险信息，包括保持生殖器卫生、多喝水以及在出现任何症状时尽早咨询医生。
